Related by context. All words. (Click for frequent words.) 78 copies mL 77 HCV RNA 73 plasma HCV RNA 73 HBV DNA 72 copies ml 71 IU ml 71 serum HCV RNA 71 log# reduction 70 log# copies mL 68 undetectable HCV RNA 68 HIV RNA 68 serum HBV DNA 68 HBV DNA levels 67 ng dL 67 detectable HCV RNA 66 HBeAg seroconversion 66 log# 66 pg mL 66 RNA copies mL 66 mg TID 66 μmol L 66 mg QD 65 peginterferon alfa 2a 65 sUA 65 alanine aminotransferase ALT 65 #.#mg/dL 65 viral load 65 pg ml 64 CrCl 64 mcg kg 64 -#.# mg dL [002] 64 cells uL 64 CDAI score 64 -#.# log# 64 ug dose 64 lopinavir r arm 64 -#.# log# copies mL 64 mcg BID 64 pmol L 64 atazanavir ritonavir 64 undetectable viral load 64 mEq L 64 ug kg 64 ALT normalization 64 fasting plasma glucose FPG 63 mcg mL 63 CIMZIA TM 63 creatinine ratio 63 cEVR 63 μg kg 63 Index CDAI 63 HCV viral 63 virologic response 62 rapid virologic response 62 alanine aminotransferase 62 mL/min/#.# m2 62 serum aminotransferase levels 62 abacavir lamivudine 62 sUA levels 62 μg doses 62 achieved ACR# 62 μg mL 62 Peg IFN 62 mg kg dose 62 ng mL 62 log# IU mL 62 urine albumin 62 lopinavir r 62 ribavirin therapy 62 baseline HbA1c 61 Crohn Disease Activity 61 mIU ml 61 serum potassium 61 undetectable viral 61 virologic failure 61 x ULN 61 mg/m2/day 61 undetectable virus HCV 61 HbA1c levels 61 mcg dose 61 mg qd 61 corticosteroid dose 61 mmol l 61 p = #.# [004] 61 μg ml 61 virologic response EVR 61 hours postdose 61 HBeAg negative patients 61 plus ribavirin 61 mg/m2 dose 61 adefovir treated 61 amoxicillin clavulanate 61 PegIFN RBV 61 serum urate 61 % CI #.#-#.# [003] 61 DAS# [002] 61 μSv 61 #mg/day [001] 60 #μg [002] 60 ng ml 60 sustained virologic response 60 ng dl 60 ug mL 60 HI titers 60 antibody titer 60 aminotransferase elevations greater 60 #mg/kg [002] 60 serum phosphorus 60 statistical significance p 60 biochemical relapse 60 CCyR 60 % Confidence Interval 60 MADRS score 60 g dl 60 #mg/day [002] 60 undetectable HBV DNA 60 p = #.# [002] 60 placebo p = 60 mg m² 60 mg BID 60 Index CDAI score 60 glycated hemoglobin levels 60 viral loads 60 calculated creatinine clearance 60 mg tid 60 Peginterferon Alfa 2a 60 hemoglobin A1c HbA1c 60 pegylated interferon alpha 60 ACR# response 60 mL sec 60 viral titer 59 Cmax 59 recurrent genital herpes 59 μg L 59 #mg BID [003] 59 fasting plasma glucose 59 Pegasys ® 59 placebo p 59 baseline A1C 59 mg orally 59 leukocyte count 59 lispro 59 HbA 1c 59 mcg albinterferon alfa 2b 59 aspartate aminotransferase 59 -#.# mg dL [001] 59 PSA nadir 59 lumbar spine BMD 59 seroconversion 59 g dL 59 microg 59 lymphocyte count 59 HbA1c 59 mL/min/#.# m 2 59 ritonavir boosted 59 statistically significant p 59 CK # plasma concentrations 59 seroconverted 59 #mg BID [001] 59 #μg [001] 59 mg/m2 59 tolterodine ER 59 neutrophil count 59 Hb A1C 59 % CI #.#-#.# [006] 59 ribavirin RBV 59 lactate dehydrogenase 59 #mg/dl 59 nmol liter 59 HCV Genotype 59 μg dose 59 #.#/#.# mm Hg [003] 59 mg ustekinumab 59 oxycodone CR 59 IFN α 59 CD4 + cell 59 HBeAg 59 CDAI 59 HBeAg positive patients 59 3mg/kg 59 adjunctive placebo 59 Pegasys plus Copegus 59 glycosylated hemoglobin HbA1c 59 creatinine clearance 58 LPV r 58 elevated ALT 58 virologic breakthrough 58 P = .# 58 Viral load 58 mIU mL 58 HbA 1c levels 58 Rapid Virological Response 58 mg dL 58 cells/mm3 58 certolizumab 58 PEG Interferon alfa 58 viremia 58 timepoint 58 IPSS 58 X ULN 58 microliter 58 chlorambucil 58 normal ULN 58 severe neutropenia 58 experienced virologic failure 58 LEXIVA r 58 annualized relapse 58 NPH insulin 58 Psoriasis Area 58 #mg q8h 58 fluticasone salmeterol 58 microgram kg 58 uM 58 EDSS score 58 sustained virological response 58 pegIFN 58 concentration Cmax 58 seroprotection 58 4mg/kg 58 serum testosterone 58 cells mcL 58 adefovir 58 mcg QD 58 ertapenem 58 neutrophil counts 58 A1C levels 58 ìg 58 NovoLog ® Mix 58 CR nPR 58 tPSA 58 ug ml 58 IIIa inhibitors 58 Engerix B 58 antibody titers 58 coinfected 58 achieved statistical significance 58 nM 58 infliximab monotherapy 58 mg d 58 response CCyR 58 administered subcutaneously 58 mg kg 58 cells μL 58 â ‰ ¥ 58 virological response 58 PegIFN 58 aspartate aminotransferase AST 58 alfa 2a 58 chronic HCV genotype 58 mmHg systolic 58 IgG antibody 58 posttreatment 58 8mg/kg 58 HBsAg 58 #mg/m# [001] 58 peginterferon alfa 2b 58 clodronate 58 plasma glucose 58 fraction LVEF 58 Acetate Rectal Suppositories 58 μg d 57 naïve HCV 57 q#h 57 HbA1C 57 seropositive patients 57 mmol L 57 median PFS 57 complete cytogenetic response 57 REYATAZ r arm 57 relapsed MM 57 TDF FTC 57 lactate dehydrogenase LDH 57 XIENCE V PROMUS Stent 57 -#.# ± [002] 57 mg subcutaneously 57 salmeterol fluticasone propionate 57 #.#/#.# mmHg [001] 57 Lupuzor ™ 57 SVR# 57 mcL 57 ABC/3TC 57 ALT elevation 57 nucleoside naive 57 urate lowering therapy 57 MIC# [001] 57 piperacillin tazobactam 57 HCV genotype 1 57 ritonavir boosted atazanavir 57 μmol l 57 #ug [001] 57 p = .# [002] 57 hypophosphatemia 57 pegylated interferon 57 spontaneous bowel movements 57 PSADT 57 tipranavir r 57 baseline FEV 57 #.#mg/kg [002] 57 μg 57 evaluable subjects 57 REMICADE monotherapy 57 serum creatinine 57 #.#ng/ml 57 undetectable hepatitis C 57 plus methotrexate 57 mg simvastatin 57 CCR5 tropic HIV 57 specific antigen PSA 57 CRp 57 5-FU/LV 57 efavirenz EFV 57 saline placebo 57 seronegative 57 treatment naive genotype 57 μg dL 57 median CD4 57 HCV genotype 57 peginterferon 57 QTcF 57 #ng/ml 57 PASI scores 57 genotypic resistance 57 genotype 1b 57 mm Hg systolic 57 oxycodone IR 57 CK MB 57 % CI #.#-#.# [007] 57 serum uric acid 57 A1c levels 57 ml kg 57 HBeAg positive 57 glomerular filtration rate 57 LANTUS R 57 3mg 57 mg dose 57 ULORIC 57 Solid Tumors criteria 57 PREZISTA ritonavir 57 budesonide pMDI 57 MBq 57 mcg doses 57 plus prednisone prednisolone 57 highly emetogenic 56 YMRS 56 AUC0 56 serum ALT 56 achieved PASI 56 #mg QD [002] 56 mEq 56 mcg Albuferon 56 pyrazinamide 56 plasma uric acid 56 DAS# CRP 56 PREZISTA r 56 ≥ 56 confidence interval #.#-#.# 56 NNRTI resistance 56 apolipoprotein B 56 pCR 56 preintervention 56 placebo PBO 56 rapid virological response 56 null responders 56 micrograms mL 56 FEV1 56 mmHg diastolic 56 CSBMs 56 p = 56 Score DAS# 56 HOMA IR 56 indinavir 56 binary restenosis 56 interquartile range 56 PaO 2 56 anemia hemoglobin 56 dapagliflozin plus 56 statin monotherapy 56 nmol L 56 HBeAg negative 56 mg dl 56 Hazard Ratio HR 56 serum phosphate 56 cytarabine daunorubicin 56 oral glucose tolerance 56 peginterferon alfa 2a #KD 56 Montgomery Asberg Depression 56 Median PFS 56 TMC# r 56 DAS# remission 56 oral allopurinol 56 posaconazole 56 serum urate levels 56 receiving VICTRELIS 56 rFSH 56 low dose Iluvien 56 mg RDEA# 56 complete cytogenetic 56 mg dosed twice 56 CI -#.# 56 serum phosphorous 56 interleukin IL -6 56 Hb A1c 56 telaprevir dosed 56 interferon alfa 2a 56 timepoints 56 mg/m2 IV 56 serum CRP 56 #mg doses [002] 56 amprenavir 56 fasting triglyceride levels 56 #ug [002] 56 PEG IFN 56 octreotide LAR 56 fosamprenavir 56 mCi m 2 56 estimated glomerular filtration 56 q8h 56 plus OBT 56 viral kinetics 56 viral suppression 56 umol L 56 SGPT 56 eGFR 56 ml min 56 REYATAZ r 56 titers 56 intramuscularly 56 baseline LDH 56 OGTT 56 nanomolar 56 IRLS score 56 urinary albumin 56 mg Lucentis 56 antiretroviral naive 56 Rapid Virologic Response 56 mU liter 56 glycated hemoglobin HbA1c 55 dose cohort 55 pegylated interferon alfa 55 HAQ DI 55 serum prostate 55 mCi 55 PROCTOCORT ® Suppository Hydrocortisone 55 serum phosphorus levels 55 pCi l 55 Durezol 55 RGT arm 55 intramuscular dose 55 hemagglutination inhibition 55 pg g 55 fructosamine 55 achieved undetectable HCV 55 progression TTP 55 oral FTY# 55 BPRS PSS 55 APTIVUS r 55 serum creatinine levels 55 comparator arm 55 mU L 55 HCV RESPOND 2 55 HAM D# scores 55 insulin detemir 55 placebo fluoxetine 55 #mg/m# [002] 55 hepatitis C genotype 55 glycated hemoglobin 55 isoprostane 55 mIU L 55 serum concentrations 55 elevated transaminases 55 alanine transaminase 55 BARACLUDE ® 55 HCV genotypes 55 Mg Usa 55 plus dexamethasone 55 pegylated interferon alfa 2a 55 p = NS 55 tamsulosin 55 Copegus 55 glycosylated hemoglobin 55 treatment naïve genotype 55 PREZISTA r arm 55 baseline serum creatinine 55 erythrocyte sedimentation rate 55 Virologic 55 hemoglobin Hb 55 #mg/kg [001] 55 #mg/dL [002] 55 peg IFN 55 Q2W 55 serum magnesium 55 albumin excretion rate 55 p = #.# [003] 55 Sustained virologic response 55 seroprotective 55 ACR# responses 55 overt nephropathy 55 lopinavir ritonavir Kaletra 55 baseline Hb 55 troponin T 55 mg kg hr 55 nmol 55 iPTH 55 plasma concentrations 55 e antigen HBeAg 55 FOLFOX6 55 serum PTH 55 achieved sustained virological 55 TAXUS p value 55 Flu Cy 55 dosing cohorts 55 achieved CCyR 55 IFN alpha 55 ADAS cog 55 mcg 55 titrated glipizide 55 atorvastatin #mg 55 postintervention 55 virological failure 55 nmol l 55 glulisine 55 transdermal estradiol 55 #mmHg [001] 55 serum IGF 55 uL 55 partial remissions 55 hemoglobin A1c levels 55 Peginterferon 55 cervical intraepithelial neoplasia 55 ALT elevations 55 urinary N telopeptide 55 Fasting blood glucose 55 postmenopausal osteoporotic women 55 per deciliter mg 55 mg eq 55 virologic suppression 55 postdose 55 % CI #.#-#.# [004] 55 peripheral blood mononuclear 55 IQR 55 liver histology 55 trough FEV1 55 ALT flares 54 mu g 54 Primary endpoints 54 lamivudine 54 gastric pH 54 transaminases 54 HIV uninfected 54 Negative Syndrome 54 A1C 54 cGy 54 confidence interval CI 54 lopinavir 54 linezolid 54 NRTI resistance 54 subcutaneous enoxaparin 54 moderate renal impairment 54 tipranavir ritonavir 54 test OGTT 54 aminotransferase levels 54 mesalamine granules 54 Expanded Disability Status 54 Score IPSS 54 lowest tertile 54 bronchodilation 54 VELCADE melphalan 54 CIMZIA ™ 54 mU 54 mRCC 54 Ishak fibrosis score 54 HCV replicon 54 serum sodium concentration 54 incontinence episodes 54 PEG Intron 54 MADRS 54 TNF alpha IL 54 thyroglobulin 54 virologic 54 adalimumab 54 Prograf ® 54 plus GP IIb 54 valacyclovir 54 hemoglobin A1C 54 mL min 54 CANCIDAS 54 Pred Forte 54 pmol liter 54 RECIST criteria 54 low dose cytarabine 54 estimated GFR 54 IGFBP 54 endoscopic remission 54 8mg 54 Copegus ribavirin 54 recurrent atrial fibrillation 54 humanized interleukin 6 54 Secondary endpoints included 54 Hemoglobin A1c HbA1c 54 generalized edema 54 Severity Index PASI 54 Indacaterol 54 mcg kg min 54 Rating Scale MADRS 54 mm Hg diastolic 54 Pharmacokinetic parameters 54 evaluable patients 54 -5 -6 54 daunorubicin 54 baseline CD4 54 treatment naļve 54 ACR# [002] 54 biphasic insulin aspart 54 nevirapine Viramune 54 QD dosing 54 #.#-#.# [011] 54 #.#g/day 54 #mg #mg #mg [003] 54 unfractionated heparin UFH 54 microalbumin 54 5mg/kg 54 Secondary endpoints include 54 Solid Tumors RECIST 54 #mg QD [001] 54 IV bolus 54 nucleotide analog 54 Kaplan Meier estimate 54 receiving prophylactic anticoagulation 54 lamivudine refractory patients 54 placebo dexamethasone 54 g dietary fiber 54 serum cortisol 54 leukopenia 54 clinically meaningful improvement 54 n = 54 Response Evaluation Criteria 54 P ≤ 54 sd = 54 RECIST Response Evaluation Criteria 54 #mg/dL [001] 54 CR CRu 54 ULN 54 #mg BID [002] 54 mg calcium 54 prospectively defined 54 Mg Uk 54 plasma leptin 54 BENICAR HCT 54 hip BMD 54 achieved sustained virologic 54 ACR Pedi 54 dasatinib Sprycel ® 54 fasting blood glucose 54 mg dosed 54 doxazosin 54 mg kg intravenously 54 serum PSA 54 plus MTX 54 NIH CPSI 54 rizatriptan 54 highest tertile 54 IgG antibodies 54 plasma glucose levels 54 IBDQ 54 hemoglobin concentrations 54 boosted atazanavir 53 intravenous bolus 53 detemir 53 Sustained Virological Response 53 imipenem 53 HDRS 53 confidence intervals CIs 53 aminotransferases 53 dacarbazine 53 anti HBs 53 BENICAR 53 NMIBC 53 OADs 53 T2 lesion volume 53 mmol 53 hematological parameters 53 cART 53 mucosal healing 53 baseline neutrophil counts 53 MCyR 53 Tipranavir 53 kBq kg 53 mg BID dose 53 NNT = 53 mCi kg 53 viral titers 53 serum lipid levels 53 g trans fats 53 Median progression 53 diuretic chlorthalidone 53 IFN alfa 53 peginterferon alfa 53 serum thyroglobulin 53 scores TNSS 53 autoantibody positive 53 HPV-#/# 53 hydroxyvitamin D levels 53 Lantus ® 53 fasting glucose 53 IELT 53 International Prostate Symptom 53 rheumatoid factor 53 - -Books Market Segmentation 53 IOP lowering 53 oral rivaroxaban 53 ‰ ¥ 53 receiving INTRON 53 FOLFOX 53 intercellular adhesion molecule 53 elevated creatinine 53 FOLFIRI alone 53 SGOT 53 SBMs 53 activated partial thromboplastin 53 plus glycoprotein IIb 53 lumbar spine bone 53 advanced adenomas 53 REYATAZ ® 53 ALVESCO 53 intact parathyroid hormone 53 Pegasys peginterferon alfa 2a 53 Aptivus ® 53 plasma folate 53 randomized #:# 53 Scale EDSS 53 NT proBNP concentrations 53 TIMP 53 TIMP 1 53 entecavir 53 tipranavir 53 SCr 53 nmol L. 53 cTnI 53 % CI #.#-#.# [008] 53 SELENA SLEDAI score 53 p# antigen 53 oral antidiabetic medication 53 Viread Emtriva 53 pT3 53 Montgomery Åsberg Depression 53 dalteparin 53 plasma concentration Cmax 53 LVEF 53 mL kg 53 DLTs 53 bcr abl 53 lopinavir ritonavir plus 53 plus prednisone 53 Alanine 53 cTnT 53 aged ≥ 53 IR Cysteamine 53 recurrent VTE 53 9mg 53 BCG vaccinated 53 BUPHENYL R sodium phenylbutyrate 53 HbA1C levels 53 mg q8h 53 gemcitabine cisplatin 53 Chronic Hepatitis C 53 confirmed CCyR 53 balsalazide 53 oblimersen 53 eosinophil count 53 μM 53 adenoma recurrence 53 anthracycline taxane 53 Cream USP 1 53 ® emtricitabine 53 biochemical recurrence 53 dexamethasone Decadron 53 null responder HCV 53 Target Lesion Revascularization TLR 53 antiretroviral naïve 53 oral diclofenac 53 plasma viremia 53 desvenlafaxine succinate 53 oral vancomycin 53 Naive Patients 53 seropositivity 53 CD4 cell 53 Apidra ® 53 plasma urate 53 salmeterol fluticasone 53 lamivudine monotherapy 53 Elitek 53 mmol L. 53 racemic albuterol 53 autoantibody levels 53 μg l 53 KRAS mutations occur 53 titer 53 QIDS SR 53 creatinine 53 ibandronate 53 nicardipine 53 enfuvirtide 53 Platelet counts 53 mTSS 53 NOAEL 53 preoperative PSA 53 mg kg Hematide 53 prednisone prednisolone plus 53 COPEGUS 53 quetiapine XR 53 del 5q MDS 53 pegylated interferon alfa 2b 53 moderately emetogenic 53 lymphocytosis 53 mL 53 mcg ml 53 Visual Analogue Scale VAS 53 gout flares 53 lanthanum carbonate 53 ACR# ACR# 53 zonisamide SR 53 nadolol 53 plus aztreonam 53 active comparator 53 K ras mutations 53 atheroma volume 53 HER2 expression 53 COMBIVIR 53 blood Phe 53 serum potassium levels 53 morphometric vertebral fractures 53 sensitivity specificity 53 microalbumin test 53 #mg dose [002] 53 degarelix 53 mg m 53 mcg linaclotide 53 adjunctive ABILIFY 53 mmHg 53 CLL SLL 53 CsA 53 dosing interval 53 ARB telmisartan 53 Tumor shrinkage 53 underwent surgical resection 53 FOLFOX4 alone 53 Scale PANSS 53 microgram mcg 53 undetectable viral loads 52 HBeAg + 52 pfu 52 pretreatment baseline 52 seropositive 52 mg p = 52 nasal symptom 52 nadir CD4 cell 52 transaminase 52 PEGASYS ® 52 potent CYP#A# inhibitors 52 ddI 52 posttransplant 52 EDSS scores 52 Valcyte 52 transaminase levels 52 simvastatin #mg 52 antiviral efficacy 52 atazanavir Reyataz 52 azathioprine monotherapy 52 fasting triglycerides 52 placebo 52 TPV r 52 pentoxifylline 52 peg interferon 52 rifabutin 52 p ≤ 52 mm ³ 52 antiviral activity 52 FluCAM 52 evaluable 52 Severity MSCS score 52 titrated glipizide plus 52 mg 52 tapentadol ER 52 #-#,# mg 52 ritonavir Norvir 52 glyburide 52 TEAEs 52 paricalcitol 52 mm3 52 viral tropism 52 Fasting plasma glucose 52 hypokalemia 52 F FDG PET 52 R entecavir 52 free survival PFS 52 prior chemotherapy regimens 52 FFNS 52 fluorouracil leucovorin 52 steroid dexamethasone 52 urinary albumin excretion 52 emtricitabine tenofovir 52 refractory NSCLC 52 urinary excretion 52 CI #.#-#.# [001] 52 Knodell necroinflammatory score 52 Pharmacokinetics PK 52 stage IIIb IV 52 inflammatory lesions 52 postvaccination 52 virologic responses 52 #mcg [003] 52 nanograms per 52 methotrexate monotherapy 52 μg liter 52 alpha 2a 52 CNS LS 52 PANSS 52 postop 52 macroalbuminuria 52 tenofovir emtricitabine 52 FOLFOX4 52 febrile neutropenia 52 serum IgG 52 darunavir r 52 achieve sustained virological 52 femtogram 52 caspofungin 52 splenectomized 52 CIMZIA TM certolizumab pegol 52 Hemoglobin A1c 52 mg administered orally 52 neutralizing antibody 52 #.#mmHg 52 argc 52 per milliliter 52 low dose ritonavir 52 piotr.skolimowski @ thomson.com 52 permanently discontinue Vectibix 52 PEGylated anti 52 Secondary endpoints 52 epoetin alpha 52 mg subcutaneous 52 EpCAM expression 52 severe renal impairment 52 metastatic GIST 52 darbepoetin alfa 52 albumin excretion 52 serum homocysteine 52 CI #.#-#.# [002] 52 serum folate 52 nelfinavir 52 BMS p = 52 mg Proellex 52 dizziness nausea diarrhea 52 protein excretion 52 refractory ischemia 52 #.#mmol L [002] 52 CC genotype 52 nodular partial response 52 Kinoid 52 blood Phe levels 52 NIHSS 52 Paraplatin ® 52 Eur J Endocrinol 52 PANSS total 52 inhibitor RG# 52 HCV infected 52 milligrams mg 52 MMSE score 52 Scale EDSS score 52 Free Survival PFS 52 protease inhibitor mutations 52 -#.# ± [001] 52 micro sieverts 52 blood phenylalanine Phe 52 splenectomized patients 52 Alzheimer Disease Assessment 52 FTE staffing 52 interferon alfa 2b 52 tobramycin inhalation solution 52 alteplase 52 Navelbine 52 subcutaneously administered 52 Treatment Naive Patients 52 KRAS mutant tumors 52 PON1 enzyme 52 hypoglycemic events 52 gm dl 52 pegylated alpha interferon 52 mRS 52 nondiabetic patients 52 prospectively stratified 52 q#d 52 standard chemotherapy regimen 52 trimethoprim sulfamethoxazole 52 mmol liter 52 titres 52 cytogenetic response 52 pulmonary exacerbations